Prothena Corp Public (PRTA) Share-based Compensation (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly Share-based Compensation came in at $6.9 million in Q1 2026, down 36.84% year-on-year from $10.9 million in Q1 2025, and down 2.25% quarter-over-quarter from $7.1 million in Q4 2025.
Prothena Corp Public (PRTA) Share-based Compensation (2012 - 2026) Analysis & Trends
Prothena Corp Public's Share-based Compensation history runs 15 years deep, the most recent figure standing at $6.9 million for Q1 2026.
- On a quarterly basis, Share-based Compensation fell 36.84% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $33.6 million, a 2861.38% increase from a year earlier, with the FY2025 full-year figure at $37.6 million, up 17245.62% from the prior year.
- Share-based Compensation slipped to $6.9 million in Q1 2026 per PRTA's latest filing, from $7.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $31.2 million in Q4 2022 and bottomed at -$35.2 million in Q4 2024.
- The 5-year median for Share-based Compensation is $10.1 million (2023), against an average of $8.3 million.
- Across the five-year window, Share-based Compensation jumped 233.79% in 2022 and tumbled 417.93% in 2024, its largest moves.
- Year by year, Share-based Compensation stood at $31.2 million in 2022, then sank by 64.45% to $11.1 million in 2023, then tumbled by 417.93% to -$35.2 million in 2024, then soared by 120.08% to $7.1 million in 2025, then fell by 2.25% to $6.9 million in 2026.
- Per Business Quant, the three latest PRTA Share-based Compensation figures stand at $6.9 million (Q1 2026), $7.1 million (Q4 2025), and $7.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Prothena Corp Public | 458.13 Mn | 128.67 Mn | - | 6.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.92 Mn |
| Mar 31, 2026 | 6.92 Mn |
| Dec 31, 2025 | 7.07 Mn |
| Dec 31, 2025 | 7.07 Mn |
| Sep 30, 2025 | 7.20 Mn |
| Sep 30, 2025 | 7.20 Mn |
| Jun 30, 2025 | 12.42 Mn |
| Jun 30, 2025 | 12.42 Mn |
| Mar 31, 2025 | 10.95 Mn |
| Mar 31, 2025 | 10.95 Mn |
| Dec 31, 2024 | -35.23 Mn |
| Dec 31, 2024 | -35.23 Mn |
| Sep 30, 2024 | 11.02 Mn |
| Sep 30, 2024 | 11.02 Mn |
| Jun 30, 2024 | 12.04 Mn |
| Jun 30, 2024 | 12.04 Mn |
| Mar 31, 2024 | 12.38 Mn |
| Mar 31, 2024 | 12.38 Mn |
| Dec 31, 2023 | 11.08 Mn |
| Dec 31, 2023 | 11.08 Mn |